Related Experiment Video

Updated: Jun 28, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

374

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

Jang Won Son1, Soo Lim2

  • 1Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea.

Endocrinology and Metabolism (Seoul, Korea)
|April 16, 2024
PubMed

Insights

Novel glucagon-like peptide-1 (GLP-1) based drugs offer new targeted obesity treatments. These incretin mimetics show promise in managing weight and related health issues, advancing therapeutic strategies.

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Obesity is a major risk factor for type 2 diabetes and cardiovascular disease.
  • Traditional lifestyle interventions are often insufficient for obesity management.
  • Targeted therapies focusing on neuroendocrine mechanisms are needed.

Purpose of the Study:

  • To review the development and clinical efficacy of novel GLP-1 based therapeutics for obesity.
  • To explore the role of incretin mimetics targeting G-protein-coupled receptors in energy balance.
  • To discuss advancements in multiagonist therapies for obesity management.

Main Methods:

  • Review of scientific literature on GLP-1 based drugs and related therapeutics.
  • Analysis of clinical efficacy data for emerging obesity management drugs.
  • Exploration of signaling pathways and neuroendocrine mechanisms in obesity.

Main Results:

  • Novel GLP-1 based drugs (semaglutide, tirzepatide) represent a significant advancement in obesity treatment.
  • Incretin mimetics targeting GLP-1, GIP, and glucagon receptors are effective in regulating body fat and energy balance.
  • Development of multiagonists (e.g., GLP-1-glucagon, GIP-GLP-1-glucagon agonists) shows therapeutic potential.

Conclusions:

  • GLP-1 based therapeutics have revolutionized obesity management.
  • Targeting nutrient-stimulated hormone pathways offers precise therapeutic strategies.
  • Future research should focus on optimizing multiagonist therapies and addressing challenges in obesity treatment.
Keywords:
GlucagonGlucagon-like peptide-1 receptor agonistsGlucose-dependent insulinotropic polypeptideMultiagonistObesity

More Related Videos

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

9.3K
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

94.4K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
257
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
182
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
275
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
195